血浆载脂蛋白C-I截短与糖尿病风险的关系:来自动脉粥样硬化多种族研究和ACT NOW预防糖尿病研究
在动脉粥样硬化多种族研究(MESA)的4,742例非糖尿病参与者和ACT NOW研究的524例糖尿病前期参与者中,血浆载脂蛋白C-I截短比例(C-I'/C-I)较高与糖尿病风险降低相关(MESA中HR 0.87,ACT NOW中HR 0.66),并与空腹血糖、HOMA-IR、OGTT葡萄糖曲线下面积增幅较小及Matsuda胰岛素敏感指数增幅较大相关。
要点
- MESA中C-I'/C-I每升高1个标准差,糖尿病风险HR 0.87(95%CI 0.79-0.95)。
- ACT NOW中C-I'/C-I较高者糖尿病风险HR 0.66(95%CI 0.48-0.91)。
- 总载脂蛋白C-I浓度与空腹血糖、HOMA-IR变化及糖尿病发生无关联。
核心结论
- 载脂蛋白C-I截短可能参与血糖水平、胰岛素抵抗和糖尿病风险的变化。
研究设计与样本
- 在MESA的4,742例非糖尿病参与者和ACT NOW研究的524例糖尿病前期参与者中,于基线采用质谱免疫分析法测定血浆载脂蛋白C-I蛋白异构体。
主要发现
- MESA中C-I'/C-I较高与糖尿病风险降低相关(564例事件;每SD的HR 0.87,95%CI 0.79-0.95;P=0.0036;中位随访9年),并与空腹血糖增幅较小(-0.5%;P<0.0001)和HOMA-IR增幅较小(-2.9%;P=0.011)相关。
- ACT NOW中C-I'/C-I较高与OGTT葡萄糖曲线下面积增幅较小(-1.8%;P=0.0052)、Matsuda胰岛素敏感指数增幅较大(7.2%;P=0.0095)及糖尿病风险降低相关(59例事件;HR 0.66,95%CI 0.48-0.91;P=0.004;中位随访2.5年)。
- MESA中总载脂蛋白C-I浓度与空腹血糖、HOMA-IR变化或糖尿病发生无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Higher truncated-to-native apolipoprotein (apo) C-I proteoform ratios (C-I'/C-I) are associated with favorable cardiometabolic risk profiles, but their relationship with longitudinal changes in insulin resistance (IR) and incident diabetes is unknown. RESEARCH DESIGN AND METHODS: Plasma apoC-I proteoforms were measured by mass spectrometry immunoassay at baseline in 4,742 nondiabetic participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and 524 participants with prediabetes in the Actos Now for Prevention of Diabetes (ACT NOW) study. The primary outcome was incident diabetes (fasting glucose [FG] ≥7.0 mmol/L or hypoglycemic medication use in MESA; FG ≥7.0 mmol/L or 2-h glucose ≥11.1 mmol/L in an oral glucose tolerance test [OGTT] in ACT NOW). Secondary outcomes were changes in FG and HOMA-IR in MESA, and OGTT-glucose area under the curve (AUCglucose) and Matsuda insulin sensitivity index (ISI) in ACT NOW. RESULTS: In MESA, a higher C-I'/C-I was associated with lower risk of diabetes (n = 564 events; HR 0.87 [95% CI 0.79, 0.95] per SD; P = 0.0036; median follow-up, 9 years), and smaller increases (follow-up adjusted for baseline) in FG (-0.5%; P < 0.0001) and HOMA-IR (-2.9%; P = 0.011) after adjusting for baseline clinical and demographic covariates, including plasma triglycerides and HDL cholesterol. Total apoC-I concentrations were not associated with changes in FG, HOMA-IR, or incident diabetes. In ACT NOW, higher C-I'/C-I was associated with smaller increases in AUCglucose (-1.8%; P = 0.0052), greater increases in ISI (7.2%; P = 0.0095), and lower risk of diabetes (n = 59 events; 0.66 [95% CI 0.48, 0.91]; P = 0.004; median follow-up, 2.5 years) after adjusting for treatment group and diabetes risk factors, including plasma lipids. CONCLUSIONS: Our results indicate that apoC-I truncation may contribute to changes in glucose levels, IR, and risk of diabetes.
引用
- Koska J, Hu Y, Furtado J, et al. Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study. Diabetes Care. 2024. PMID: 39453822. doi:10.2337/dc24-1462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。